Cassidy’s Indecision Threatens Overton’s FDA Nomination Before Democratic Senate Takeover

3 min read
Source: The Washington Post
Cassidy’s Indecision Threatens Overton’s FDA Nomination Before Democratic Senate Takeover
Photo: The Washington Post
TL;DR

Senate Health Committee Chair Bill Cassidy remains undecided on Dr. Heidi Overton’s nomination to lead the FDA, citing unresolved questions about her fitness for the role. With Democrats set to take control of the Senate in January, Republicans face a narrow window to confirm her. Cassidy noted that a confirmed commissioner might offer more independence from HHS Secretary Robert F. Kennedy Jr. than a series of acting leaders, but he has not committed to a vote. The nomination faces opposition from some Republicans and Democrats, with concerns ranging from vaccine policy to the FDA’s upcoming review of mifepristone.

Key points

  • Cassidy stated on CBS’s 'Face the Nation' that he still has questions about Overton and cannot predict the outcome of the Wednesday committee vote.
  • The GOP holds a one-vote majority on the 21-member HELP committee, meaning Overton cannot afford to lose any Republican support if all Democrats oppose her.
  • Senators Susan Collins and Lisa Murkowski have also declined to commit, citing concerns about flavored vapes, political pressure on scientific reviews, and mifepristone.
  • Cassidy weighed the option of leaving the FDA vacant, noting that a permanent commissioner could establish more independence from Kennedy Jr. than acting administrators.
  • If Overton is not confirmed by January 3, her nomination would likely be returned to the White House, requiring a new nomination before a Democratic-controlled Senate.

Background

The FDA has lacked a permanent commissioner since Dr. Marty Makary resigned in May 2026. Overton, a domestic policy adviser in the White House, was nominated approximately three months after Makary’s departure. She previously served as a chief policy adviser at a conservative think tank. In September, she testified at her confirmation hearing, stating that the MMR vaccine was 'safe and effective,' a stance that appeared to diverge from HHS Secretary Kennedy Jr. However, her past comments on mifepristone have drawn scrutiny from Democrats. The White House has not indicated plans to withdraw her nomination.

How outlets are covering it

The Washington Post emphasizes the bipartisan pushback against Overton, noting opposition from some Republicans, many Democrats, and prominent Make America Healthy Again supporters. Politico highlights Cassidy’s internal deliberations and his consideration of the trade-offs between a confirmed commissioner and a series of acting leaders. The Hill focuses on Cassidy’s undecided status and the logistical challenge of confirming nominees before the Senate control shift. NBC News details the specific policy concerns raised by Senators Collins and Murkowski, including mifepristone and flavored vapes, and notes that Cassidy previously expressed 'strong concerns' about Overton’s lack of managerial experience. All sources agree that the nomination faces significant hurdles, but they differ in emphasis: The Post and Hill focus on the political opposition, while Politico and NBC News highlight the procedural and policy-specific concerns.

Why it matters

The outcome of Overton’s nomination will determine the leadership of the FDA during a period of significant policy decisions, including the safety review of mifepristone and vaccine approvals. A failure to confirm her could leave the agency led by acting administrators, potentially increasing the influence of HHS Secretary Kennedy Jr. on scientific reviews. The narrow GOP majority in the Senate makes the confirmation process highly vulnerable to opposition from any single Republican, highlighting the fragility of the administration’s agenda in the final months of their control.

What to watch

The HELP committee is scheduled to vote on Overton’s nomination this Wednesday. Cassidy and other undecided Republicans may hold further conversations with Overton and administration officials in the coming days. If the nomination fails to advance, the White House may need to decide whether to re-nominate her or select a new candidate before Democrats take control of the Senate in January.

Share this article

Want the full story? Read the original reporting

Read on The Washington Post